Protagonist Therapeutics, Inc. (PTGX) Financials

PTGX Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 697.5 million 42.0 million
Dec. 31, 2025 669.9 million 55.2 million
Sept. 30, 2025 701.7 million 56.3 million
June 30, 2025 718.0 million 50.0 million

PTGX Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -49.2 million 14.5 million
Dec. 31, 2025 -35.5 million 10.7 million
Sept. 30, 2025 -2.0 million 10.6 million
June 30, 2025 -29.6 million 10.9 million

PTGX Net Income

No data available :(

PTGX Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 547.8 million - 7.4 million
Dec. 31, 2025 567.4 million - 8.0 million
Sept. 30, 2025 576.1 million - 10.7 million
June 30, 2025 570.5 million - 11.3 million

PTGX Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 70.5 million
Dec. 31, 2025 63.6 million
Sept. 30, 2025 63.8 million
June 30, 2025 63.5 million

PTGX Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 215000 46.7 million 13.3 million -
Dec. 31, 2025 1.4 million 46.4 million 11.4 million -
Sept. 30, 2025 88000 40.0 million 11.1 million -
June 30, 2025 813000 37.0 million 10.6 million -

PTGX Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 56.4 million 407000
Dec. 31, 2025 7.4 million 376000
Sept. 30, 2025 4.7 million -
June 30, 2025 5.5 million -

PTGX Revenue by Segment
Graph available only for paid members. Upgrade to see it.

PTGX

Price: $111.93

52 week price:
49.38
111.93

Earnings Per Share: -1.81 USD

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 966400

Ebitda: -4.9 million

Market Capitalization: 6.3 billion

Links: